Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Introgen Therapeutics Inc (NasdaqNM:INGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  7Conference call: Introgen Therapeutics, Inc. Earnings (Q4 2001)
Aug  7Earnings Announcement
Location
301 Congress Avenue, Suite 1850
Austin, TX 78701
Phone: (512) 708-9310
Fax: (512) 708-9311
Email: j.albrecht@introgen.com
Employees (last reported count): 53
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 63%
·Over the last 6 months:
 · one insider sell; 20.0K shares
  (0.1% of insider shares)
·Institutional: 18% (49% of float)
(27 institutions)
·Net Inst. Buying: 514.0K shares (+11.66%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Introgen Therapeutics Inc. develops gene therapy products to treat a variety of cancers. The Company has treated over 400 patients with more than 3,000 doses of its lead product candidate, INGN 201, in over 17 completed and ongoing Phase I and Phase II clinical trials worldwide. Introgen's current and expected clinical trials evaluate the Company's products both alone and in combination with chemotherapy, radiation and/or surgery. Introgen also controls a broad intellectual property portfolio that includes more than 200 pending and issued patents for a variety of gene therapy technologies. The Company has active collaborations with numerous academic centers and pharmaceutical and biotechnology industry partners. In 1998, Introgen Therapeutics formed Gendux, a European subsidiary developing biopharmaceuticals.
More from Market Guide: Expanded Business Description

Financial Summary
Introgen Therapeutics, Inc. is a developer of gene therapy products for the treatment of a variety of cancers. For the fiscal year ended 6/30/01, total revenues decreased 38% to $5.2 million. Net loss totaled $16.4 million, up from $7.7 million. Revenues reflect decreased revenues from collaborations due to a decreased level of early stage research and development. Net loss reflects increased cost of sales as a percentage of revenues and increased interest expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

John Kapoor, Ph.D., 56
Chairman
--  
David Nance, 49
Pres, CEO, Director
$271K
James Albrecht, Jr., 46
CFO
176K
G. Thomas Finnegan, III
VP of Fin. and Corp. Devel.
--  
J. David Enloe, Jr, 36
VP-Operations
162K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:INGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 9-Apr-2001
$3.20 
Recent Price$3.98 
52-Week High
on 18-Oct-2000
$15.50 
Daily Volume (3-month avg)32.8K
Daily Volume (10-day avg)15.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change-38.8%
26-Week Change
relative to S&P500
-33.3%
Share-Related Items
Market Capitalization$84.7M
Shares Outstanding21.3M
Float7.90M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.63 
Earnings (ttm)-$1.17 
Earnings (mrq)-$0.34 
Sales (ttm)$0.32 
Cash (mrq)$1.64 
Valuation Ratios
Price/Book (mrq)1.51 
Price/EarningsN/A 
Price/Sales (ttm)12.37 
Income Statements
Sales (ttm)$5.20M
EBITDA (ttm)-$17.2M
Income available to common (ttm)-$16.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-35.78%
Return on Equity (ttm)-50.82%
Financial Strength
Current Ratio (mrq)9.77 
Debt/Equity (mrq)0.17 
Total Cash (mrq)$35.0M
Short Interest
As of 8-Aug-2001
Shares Short0 
Shares Short
(Prior Month)
1,000 
Daily Volume12.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.